David Lewis
Stock Analyst at Morgan Stanley
(2.81)
# 1,697
Out of 4,829 analysts
270
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $117 → $127 | $133.24 | -4.68% | 24 | Apr 17, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $310.67 | -3.43% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $167.22 | +64.45% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $84.67 | +7.48% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $15.08 | +4,674.54% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $30.90 | +223.62% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $111.50 | -86.55% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $3.37 | +790.21% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $56.75 | +32.16% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $17.59 | +155.83% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $68.19 | -12.01% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $55.82 | +46.90% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $125.11 | +244.50% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $83.48 | +84.48% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $18.49 | +116.33% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $73.68 | +83.22% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $380.92 | -26.49% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $536.51 | -46.88% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.68 | +184.43% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $137.70 | -31.74% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $95.75 | -17.49% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $95.21 | +89.06% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $154.22 | +21.26% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $12.65 | +255.73% | 5 | Dec 15, 2020 |
Abbott Laboratories
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $117 → $127
Current: $133.24
Upside: -4.68%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $310.67
Upside: -3.43%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $167.22
Upside: +64.45%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $84.67
Upside: +7.48%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $15.08
Upside: +4,674.54%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $30.90
Upside: +223.62%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $111.50
Upside: -86.55%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $3.37
Upside: +790.21%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $56.75
Upside: +32.16%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $17.59
Upside: +155.83%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $68.19
Upside: -12.01%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $55.82
Upside: +46.90%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $125.11
Upside: +244.50%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $83.48
Upside: +84.48%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $18.49
Upside: +116.33%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $73.68
Upside: +83.22%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $380.92
Upside: -26.49%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $536.51
Upside: -46.88%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.68
Upside: +184.43%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $137.70
Upside: -31.74%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $95.75
Upside: -17.49%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $95.21
Upside: +89.06%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $154.22
Upside: +21.26%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $12.65
Upside: +255.73%